Bioanalytical Testing: A Reliable Partner in Clinical Trials

What Is Bioanalytical Analysis? Laboratory Support

A Trusted Partner in Bioanalytical Testing: Analytical Support from Clinical Trials to Regulation

The drug development process is built on scientific accuracy and reliable data. The accuracy of results obtained in clinical trials depends largely on the quality of bioanalytical analyses. In particular, the analyses conducted in bioavailability (BA) and bioequivalence (BE) studies represent one of the most critical stages in demonstrating the safety and efficacy of newly developed or soon-to-be-approved drugs.

Nanolab Laboratories Group conducts bioanalytical analyses for bioavailability and bioequivalence studies carried out in accordance with Good Clinical Practice (GCP) guidelines, under the operating license granted by the Ministry of Health. In addition, through GLP-compliant analyses, laboratory support for Phase I–III clinical trials, and pharmaceutical analysis services, the group serves as a solution partner at various stages of the drug development process.

Competent Services with a Ministry of Health Operating License

Nanolab Laboratories Group has successfully completed the inspection processes conducted by the Turkish Medicines and Medical Devices Agency (TİTCK) and operates in accordance with the Regulation on Clinical Trials of Human Medicinal Products. In accordance with this operating license, the bioanalytical department provides analysis services for bioavailability and bioequivalence studies, contributing to the pharmaceutical industry with a quality approach that complies with national and international regulations.

What Is Bioanalytical Analysis?

Bioanalytical analyses are advanced analytical tests that enable the precise, accurate, and reliable measurement of active pharmaceutical ingredients and, when necessary, their metabolites in biological samples (blood, plasma, serum, etc.) collected from volunteers or patients participating in clinical trials.

Thanks to these analyses, the following aspects of the drug can be determined:

• Rate of absorption into the bloodstream
• Concentration in the blood
• Absorption, distribution, metabolism, and excretion (ADME) processes
• Pharmacokinetic parameters

are scientifically evaluated.

The data obtained constitute one of the most critical decision-making mechanisms in the drug development process.

The Importance of Bioavailability and Bioequivalence Studies

Bioavailability (BA) refers to how much of the active ingredient in an administered drug reaches the systemic circulation and how quickly it does so. This data is critical for understanding how the drug behaves in the body and for determining the appropriate dose.

Bioequivalence (BE), on the other hand, indicates that a generic product demonstrates statistically similar performance to the reference product in terms of bioavailability. Bioequivalence studies scientifically demonstrate that generic drugs will have the same therapeutic effect as the reference product.

These studies;

• In generic drug development processes
• In marketing authorization applications
• Formulation changes
• Validation of manufacturing processes

provide important scientific evidence.

The Role of Bioanalytical Analyses in Phase I–III Clinical Trials

Clinical trials are scientific studies that evaluate the safety and efficacy of drugs under development. While Phase I trials aim to determine the drug’s pharmacokinetic behavior in the human body, Phase II and Phase III trials focus on evaluating the drug’s efficacy and safety in larger patient populations.

Throughout these processes, reliable bioanalytical analyses;

• Generation of pharmacokinetic data
• Dose optimization
• Safety assessments
• Validation of clinical trial results

play a role.

Comprehensive Laboratory Services with Advanced Analytical Infrastructure

The Nanolab Laboratories Group offers comprehensive analytical solutions not only for bioavailability and bioequivalence studies but also for various stages of the drug development process.

Our Services:

• Bioanalytical analyses under GLP
• Laboratory support for Phase I–III clinical trials
• Bioavailability (BA) and bioequivalence (BE) analyses
• LC-MS/MS-based bioanalytical analyses
• Analytical method development and method validation
• Biological sample analyses and data reporting services
• Stability studies
• Pharmaceutical analyses
• Nitrosamine analyses

Thanks to our expert team and advanced analytical instrumentation infrastructure, we provide customized solutions for every project, delivering reliable, reproducible, and regulatory-compliant analytical results.

Your Trusted Partner in Clinical Trials and Drug Development

The success of clinical trials depends not only on well-designed studies but also on reliable laboratory data. As Nanolab Laboratories Group, we provide bioanalytical and pharmaceutical analysis services that comply with national and international standards to pharmaceutical companies, CROs, bioavailability and bioequivalence centers, and research institutions.

With our quality-focused approach, robust technical infrastructure, and team of experts, we continue to be your trusted partner at every stage of the drug development process.

For all your inquiries, contact us.
For the latest news and updates about our services, you can follow us on LinkedIn.
To stay updated on our latest blog posts, follow our Instagram account.